Literature DB >> 1658433

[Progressive cytomegalovirus encephalitis in successful ganciclovir therapy of cytomegalovirus retinitis in an AIDS patient].

S Ewig1, E Bierhoff, W Luster, A Steudel, D Niese.   

Abstract

We describe a case of an HIV-infected intravenous drug-abuser who died of progressive cytomegalovirus encephalitis despite successful treatment of cytomegalovirus retinitis with ganciclovir. On autopsy, complete remission of retinitis and widespread cytomegalovirus-encephalitis could be demonstrated. Therapeutic failure therefore seems attributable to insufficient CNS-distribution of ganciclovir rather than to ganciclovir-resistant cytomegalovirus strains.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1658433     DOI： 10.1007/bf01666835

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN： 0023-2173


  14 in total

1.  Progressive disease due to ganciclovir-resistant cytomegalovirus in immunocompromised patients.

Authors:  A Erice; S Chou; K K Biron; S C Stanat; H H Balfour; M C Jordan
Journal:  N Engl J Med       Date:  1989-02-02       Impact factor: 91.245

2.  Cytomegalovirus infection in patients with AIDS.

Authors:  W L Drew
Journal:  J Infect Dis       Date:  1988-08       Impact factor: 5.226

3.  9-(1,3-Dihydroxy-2-propoxymethyl)guanine (ganciclovir) in the treatment of cytomegalovirus gastrointestinal disease with the acquired immunodeficiency syndrome.

Authors:  A Chachoua; D Dieterich; K Krasinski; J Greene; L Laubenstein; J Wernz; W Buhles; S Koretz
Journal:  Ann Intern Med       Date:  1987-08       Impact factor: 25.391

4.  Ganciclovir for the treatment and suppression of serious infections caused by cytomegalovirus.

Authors:  O L Laskin; D M Cederberg; J Mills; L J Eron; D Mildvan; S A Spector
Journal:  Am J Med       Date:  1987-08       Impact factor: 4.965

5.  Treatment of serious cytomegalovirus infections with 9-(1,3-dihydroxy-2-propoxymethyl)guanine in patients with AIDS and other immunodeficiencies.

Authors: 
Journal:  N Engl J Med       Date:  1986-03-27       Impact factor: 91.245

Review 6.  Cytomegalovirus in the setting of infection with human immunodeficiency virus.

Authors:  R T Schooley
Journal:  Rev Infect Dis       Date:  1990 Sep-Oct

7.  CMV encephalitis during ganciclovir therapy of CMV retinitis.

Authors:  T F Schwarz; K Loeschke; I Hanus; G Jäger; W Feiden; F H Stefani
Journal:  Infection       Date:  1990 Sep-Oct       Impact factor: 3.553

8.  Survival of patients with the acquired immune deficiency syndrome after development of cytomegalovirus retinopathy. UCLA CMV Retinopathy Study Group.

Authors:  G N Holland; R F Sison; D E Jatulis; M G Haslop; M J Sakamoto; N C Wheeler
Journal:  Ophthalmology       Date:  1990-02       Impact factor: 12.079

Review 9.  Serious cytomegalovirus disease in the acquired immunodeficiency syndrome (AIDS). Clinical findings, diagnosis, and treatment.

Authors:  M A Jacobson; J Mills
Journal:  Ann Intern Med       Date:  1988-04       Impact factor: 25.391

10.  Cytomegalovirus encephalitis in acquired immunodeficiency syndrome.

Authors:  D A Hawley; J F Schaefer; D M Schulz; J Muller
Journal:  Am J Clin Pathol       Date:  1983-12       Impact factor: 2.493
View more
  2 in total

1.  Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)-cytosine and 9-(1,3-dihydroxy-2-propoxymethyl)-guanine in the treatment of intracerebral murine cytomegalovirus infections in immunocompetent and immunodeficient mice.

Authors:  J Neyts; H Sobis; R Snoeck; M Vandeputte; E De Clercq
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-04       Impact factor: 3.267

2.  Therapy and prophylaxis of opportunistic infections in HIV-infected patients: a guideline by the German and Austrian AIDS societies (DAIG/ÖAG) (AWMF 055/066).

Authors:  J Thoden; A Potthoff; J R Bogner; N H Brockmeyer; S Esser; K Grabmeier-Pfistershammer; B Haas; K Hahn; G Härter; M Hartmann; C Herzmann; J Hutterer; A R Jordan; C Lange; S Mauss; D Meyer-Olson; F Mosthaf; M Oette; S Reuter; A Rieger; T Rosenkranz; M Ruhnke; B Schaaf; S Schwarze; H J Stellbrink; H Stocker; A Stoehr; M Stoll; C Träder; M Vogel; D Wagner; C Wyen; C Hoffmann
Journal:  Infection       Date:  2013-09-14       Impact factor: 3.553
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.